Allergan's 1st Quarter In Line With Expectations
The wide-moat firm hasn't yet faced competition for Restatsis, so we think our fair value estimate stays mostly intact.
Wide-moat
Overall, performance of Allergan’s key products continues to live up to our expectations, but this year will remain a challenge from generic competition on a number of products like Restasis and Delzicol. Botox grew 12% thanks to strong U.S. therapeutic and international cosmetic sales. While facial filler growth slowed on promotional efforts, we still have an optimistic outlook for this franchise thanks to healthy demand and new products. Growth should accelerate over the back half of the year. Similarly, management’s efforts to shift CoolSculpting to direct distribution in international markets should improve from current growth affected by the transition. We still expect growth to improve in 2019 despite ongoing concerns on new competition on Botox, including the launch of competing CGRPs in migraine.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.